<DOC>
	<DOCNO>NCT00207948</DOCNO>
	<brief_summary>This feasibility study aim elevate protease inhibitor ( PI ) dosage part active antiretroviral therapy ( HAART ) . After pharmacokinetics currently prescribe PI determine , patient vIQ &lt; 1 eligible 50 % dose increase 8 week time frame vIQ would reassess determine increase PI dosage thereby increase bioavaiability would reduce viral load .</brief_summary>
	<brief_title>Optimizing Antiretroviral Therapy HIV-Infected Children Adolescents</brief_title>
	<detailed_description>Although , use protease inhibitor ( PI ) contain highly active antiretroviral therapy ( HAART ) lead remarkable improvement prognosis outcome HIV infection , 45 % 70 % treatment-na√Øve patient commence HAART achieve complete virological suppression . The emergence HIV resistance antiretroviral drug one main obstacle successful long-term suppression HIV replication . Poor adherence unfavorable pharmacokinetics ( PK ) cause altered absorption , genetic variation metabolism drug-drug interaction frequently lead antiretroviral drug concentration inhibitory concentration 50 % viral quasispecies ( IC50 ) loss viral suppression . Enzymes cytochrome ( CYP ) P450 ( CYP2C19 , CYP3A4 , CYP3A5 ) family locate liver small intestine responsible metabolism PIs . The absence expression certain enzyme family recently correlate genetic polymorphism , may major role variation cytochrome P450-mediated drug metabolism . Results study suggest significant difference distribution polymorphism associate allele ethnic group , particular Caucasians African Americans . Detection cytochrome P450 variant allele detail data allelic frequency various ethnic group critical assess impact PK antiretroviral agent , particular PIs . This research proposal aim development novel multidisciplinary approach optimize HAART HIV infect child . It increasingly clear inter-individual variation drug metabolism responsiveness strong genetic component . The metabolic pathway lead drug clearance , bio-availability , cellular response complex , begin understood . Key understand inter-individual response identification genetic polymorphism contribute variability , relative contribution different genes/SNPs , possible interaction correspond protein product pathway . We propose develop dose regimen PIs HIV-infected child take account genetic variability drug metabolism transport , resistance dominant viral strain ( determine virtual phenotype ) . In order , protocol address follow Specific Aims : - Specific Aim 1 ( complete previously ) : Determine prevalence genetic variation CYP2C19 , CYP3A4 , CYP3A5 , MDR-1 gene cohort child adolescent HIV infection . - Specific Aim 2 ( complete previously ) : Evaluate relationship genetic variability pharmacokinetic parameter ( Cmin , Cmax , AUC ) toxicity ( graded Division AIDS [ DAIDS ] classification ) protease inhibitor pediatric patient HIV infection . - Specific Aim 3 ( THIS STUDY ) : Evaluate impact dose adjustment protease inhibitor base pharmacogenetic profile virtual inhibitory quotient ( VIQ ) clinical outcome ( measure HIV-RNA viral load CD4+ cell count change ) toxicity ( graded DAIDS classification ) pediatric patient HIV infection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : Evidence HIV infection confirm positive culture PCR least two occasion , positive ELISA confirmatory Western Blot . At least one test must do ACTG certify laboratory approve perform assay protocol test Age 421 year Current use HAART regimen ( NRTI or/and NNRTI base ) contain PI HIVRNA level 1,000 copies/mL ( Stage II ) vIQ &lt; 1 Kaletra Signed informed consent , indicate , sign inform assent waiver assent . Exclusion criterion : Grade 34 DAIDS define toxicity Use cimetidine ( use internal standard HPLCMS/MS assay ) Any active opportunistic infection Any follow laboratory finding entry : absolute neutrophil count &lt; 750 cells/mm3 ; platelet count &lt; 75,000 cells/mm3 ; AST &gt; 3 time upper limit age adjust normal value ; ALT &gt; 3 time upper limit age adjust normal value ; serum creatinine &gt; 1.2mg/dL . Patients dual PI regimen ( except second PI give boost ) time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Protease Inhibitors</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Genes , MDR1 , Cytochrome P-450 enzyme</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>